ANPCY
CelLBxHealth plc·Healthcare
0.07
0.000%(+0.00)
Market ClosedLast Updated: — ET
52W L: $0.0752W H: $2.39
ANPCY NEWS
proactiveinvestors.co.uk
Feb 13
CelLBxHealth shares rise 3% as company continues to focus on cost base
Shares in CelLBxHealth PLC (AIM:CLBX, OTCQB:ANPCF, FRA:DWV) rose 3% to 1.08p on Thursday after the company announced it would discontinue its United States Food and Drug Administration establishment licence and device listing for its Parsortix system. The Guildford-based group, which provides circulating tumour cell intelligence tests and services to support cancer research and drug development, said the decision reflected its revised business model and customer usage patterns.
proactiveinvestors.co.uk
Feb 13
CelLBxHealth drops FDA device listing to cut costs and refocus on revenue growth
CelLBxHealth PLC (AIM:CLBX, OTCQB:ANPCF, FRA:DWV) has decided to discontinue maintenance of its United States Food and Drug Administration establishment licence and device listing for the Parsortix system as it seeks to strengthen cost discipline and match its regulatory approach with current commercial priorities. The Guildford-based group, which provides circulating tumour cell intelligence tests and services to support research, drug development and clinical oncology, said the decision reflected its revised business model and customer usage patterns.
proactiveinvestors.co.uk
Jan 16
CelLBxHealth backed for rebound by broker
CelLBxHealth PLC (AIM:CLBX, OTCQB:ANPCF, FRA:DWV) is a recovery story with asymmetric upside. In a note published on Friday, Cavendish reiterated its 4.0p price target, implying more than 300% upside from current levels, after the company confirmed that forecasts for 2026 to 2028 remain intact.
proactiveinvestors.co.uk
Jan 16
CelLBxHealth enters 2026 with strong pipeline
CelLBxHealth PLC (AIM:CLBX, OTCQB:ANPCF, FRA:DWV) said it is entering 2026 with a sharpened strategy and a focus on turning a £12.6 million sales pipeline into revenues, adding that its balance sheet remained robust. In an outlook statement accompanying preliminary results, the Guildford-based cancer diagnostics group said its qualified 2026/27 pipeline stood at about £12.6 million, or £4.5 million on a risk-weighted basis.
proactiveinvestors.co.uk
Jan 12
CelLBxHealth Health confirms boardroom appointments
CelLBxHealth PLC (AIM:CLBX, OTCQB:ANPCF) has confirmed board appointments signed off at a board meeting last month, with its chief executive and three non-executive directors formally taking up their roles at the cancer diagnostics company. Peter Collins takes on the role of CEO, while Klaas de Boer, Kim Oreskovic and Benjamin Hart join the board as non-executive directors.
